- Home
- ALUR vs BIVI Comparison
ALUR vs BIVI Comparison
Compare ALUR & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALUR
- BIVI
- Stock Information
- Founded
- ALUR 2009
- BIVI 2013
- Country
- ALUR United States
- BIVI United States
- Employees
- ALUR N/A
- BIVI N/A
- Industry
- ALUR
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- ALUR
- BIVI Health Care
- Exchange
- ALUR Nasdaq
- BIVI Nasdaq
- Market Cap
- ALUR 15.4M
- BIVI 14.2M
- IPO Year
- ALUR N/A
- BIVI N/A
- Fundamental
- Price
- ALUR $1.56
- BIVI $1.50
- Analyst Decision
- ALUR Buy
- BIVI
- Analyst Count
- ALUR 2
- BIVI 0
- Target Price
- ALUR $9.25
- BIVI N/A
- AVG Volume (30 Days)
- ALUR 40.6K
- BIVI 119.4K
- Earning Date
- ALUR 11-13-2025
- BIVI 11-11-2025
- Dividend Yield
- ALUR N/A
- BIVI N/A
- EPS Growth
- ALUR N/A
- BIVI N/A
- EPS
- ALUR N/A
- BIVI N/A
- Revenue
- ALUR $19,917,000.00
- BIVI N/A
- Revenue This Year
- ALUR N/A
- BIVI N/A
- Revenue Next Year
- ALUR N/A
- BIVI N/A
- P/E Ratio
- ALUR N/A
- BIVI N/A
- Revenue Growth
- ALUR N/A
- BIVI N/A
- 52 Week Low
- ALUR $1.52
- BIVI $1.42
- 52 Week High
- ALUR $19.49
- BIVI $38.50
- Technical
- Relative Strength Index (RSI)
- ALUR 22.34
- BIVI 29.30
- Support Level
- ALUR $1.61
- BIVI $1.83
- Resistance Level
- ALUR $2.03
- BIVI $1.80
- Average True Range (ATR)
- ALUR 0.10
- BIVI 0.10
- MACD
- ALUR -0.03
- BIVI -0.03
- Stochastic Oscillator
- ALUR 7.84
- BIVI 14.79
About ALUR Allurion Technologies Inc.
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.